Economic impact of hypoglycemia on healthcare in Spain

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 6, 2010, Pages 649-660

  Brito Sanfiel, M ^a   Diago Cabezudo, J ^b   Calderon, A ^c  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b JOHNSON AND JOHNSON   (United States)

^c Primary Care Center Rosa de Luxemburgo   (Spain)

Author keywords

blood glucose; cost analysis; diabetes mellitus; economics; hypoglycemia; self monitoring; Spain

Indexed keywords

GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; ORAL ANTIDIABETIC AGENT;

ABSENTEEISM; BLOOD GLUCOSE MONITORING; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; ECONOMIC EVALUATION; EDUCATION PROGRAM; HEALTH CARE COST; HEALTH PRACTITIONER; HOSPITALIZATION COST; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRODUCTIVITY; QUALITY OF LIFE; RETIREMENT; REVIEW; SELF EXAMINATION; SOCIAL CONTROL; SPAIN;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; PREVALENCE; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 78650539357     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.73     Document Type: Review

References (62)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemia. Nature 414, 782-787 (2001).
2. Diabetes Control and Complications Trials Research Group. The effect of intensive treatment of diabetes on the development and progression long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993).
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998).
4. ADVANCE Collaborative Group. Effects of intensive blood glucose control on vascular outcomes in patients with Type 2 diabetes mellitus: results of the ADVANCE trial. N. Engl. J. Med. 358, 2560-2572 (2008).
5. Diabetes Control and Complications Trials Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes 46, 271-286 (1997).
6. UK Hypoglycemia Study Group. Risk of hypoglycaemia in Types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50, 1140-1147 (2007).
7. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358(24), 2545-2559 (2008).
8. Cryer PE, Axelrod L, Grossman AB et al. Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metabol. 94, 709-728 (2009).
9. Gonzalez P, Faure E, del Castillo A. Coste de la diabetes mellitus en Espana. Med. Clin. 127(20), 776-784 (2006).
10. Leese GP, Wang J, Bromhall J. Frequency of severe hypoglycaemia requiring emergency treatment in Type 1 and Type 2 diabetes: a population-based study of health service resource use. Diabetes Care 26, 1176-1180 (2003).
11. Arroyo J, Badfa X, de la Calle H et al. Tratamiento de los pacientes con diabetes mellitus Tipo 2 en Atencion Primaria en Espana. Med. Clin. 125, 166-172 (2005).
12. Davies RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in Type 1 and Type 2 diabetes. Curr. Med. Res. Opin. 21(9), 1477-1483 (2005).
13. American Diabetes Association (ADA) workgroup on hypoglycemia. Defining and reporting hypoglycaemia in diabetes. Diabetes Care 28, 1245-1249 (2005).
14. Cryer P. The barrier of hypoglycaemia in diabetes. Diabetes 57(12), 3169-3176 (2008).
15. Reviriego J, Gomis R, Maranes JP, Ricart W, Hudson P, Sacristan JA. Cost of severe hypoglycaemia in patients with Type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia. Int. J. Clin. Pract. 62(7), 1026-1032 (2008).
16. Wright AD, Cull CA, Macleod KM, Holman RR; for the UKPDS Group. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J. Diabetes Complicat. 20(6), 395-340 (2006).
17. Donnelly LA, Morris AD, Frier BM et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population based study. Diabetes Med. 22(6), 749-755 (2005).
18. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with Type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25(2), 330-336 (2002).
19. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet. Med. 25, 245-254 (2008).
20. Fanelli CG, Porcellatti F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size of the problem. DiabetesMetab. Res. Rev. 20(Suppl. 2), S32-S42 (2004).
21. Moreno A, Sanchez P, Santiago P, Martinez P, Lopez JA, Arraiga C. Unawareness hypoglycaemia in Type 1 diabetes. Avances en Diabetologia 25, 491-493 (2009).
22. Segel SA, Paramote DS, Creyer PE. Hypoglycaemia-associated autonomic failure in advanced Type 2 diabetes. Diabetes 51, 724-733 (2002).
23. Smith CB, Choudhary P, Pernet A, Hopkins D, Amiel SA. Hypoglycaemia unawareness is associated with reduced adherence to therapeutic decisions in patients with Type 1 diabetes evidence from a clinical audit. Diabetes Care 32, 1513-1517 (2009).
24. Monereo S, Pavon I, Vega B, Elviro R. Diabetes mellitus: aproximacion al coste por proceso aplicado al paciente diabetico ingresado. Endocrinologia 44, 319-325 (1997).
25. Aguilar M, Carral F, Ortego J, Ballesta M, Olveira G. Costes economicos asociados a la diabetes Tipo 1. Avances en Diabetologia 20(Suppl. 1), 56 (2004).
26. Josson B. Revealing the cost of Type II diabetes in Europe. Diabetologia 45, S5-S12 (2002).
27. Schnell O, Hummel M, Weber C. Economic and clinical aspects of diabetes regarding self-monitoring of blood glucose. Diabetes Technol. Ther. 10(Suppl. 1), S72-S81 (2008).
28. Oliva J, Lobo F, Molina B, Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care 27, 2616-2621 (2004).
29. Mata M, Antonanzas F, Tafalla M, Sanz P. The cost of Type 2 diabetes in Spain: the CODE-2 study. Gac. Sanit. 16(6), 511-520 (2002).
30. Carral F, Oliveira G, Salas J, Garcia I, Sillero A, Aguilar M. Care resource utilization and direct costs incurred by people with diabetes in Spanish hospital. Diabetes Res. Clin. Pract. 56, 27-34 (2002).
31. Carral F, Aguilar M, Olveira G, Mangas A, Domenech I, Torres I. Increased hospital expenditures in diabetic patients hospitalized for cardiovascular disease. J. Diabetes Complicat. 17, 331-336 (2003).
32. Gisbert R, Brosa M. Health costs database. Soikos Barcelona, Spain (2004).
33. Aguilar M, Ballesta M, Carral F; Grupo de Diabetes de la SAEN. Indirect costs in Type 2 diabetes mellitus. Endocrinologia y Nutricion 49, 59-69 (2002).
34. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J. Diabetes Complicat. 18, 60-68 (2004).
35. Boyle PJ, Zreblec J. Physiological and behavioral aspects of glycemic control and hypoglycemia in diabetes. South Med. J. 100, 175-182 (2007).
36. Lopez Bastida J, Serrano P, Duque B. Los costes socioeconomicos de la diabetes mellitus. Atencion Primaria 29, 145-150 (2002).
37. Leiter LA, Yale JF, Chiasson JL, Harris SB, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycaemia episodes on glycemic and hypoglycemia management. Can. J. Diabetes 29(3), 186-192 (2005).
38. Hammer M, Lammert M, Monereo Mejias S, Kern W, Frier BM. Cost of managing severe hypoglycaemia in three European countries. J. Med. Econ. 12(4), 281-290 (2009).
39. Guisasola FA, Casal Llorente C, Rubio-Terres C. Cost analysis of Type 2 diabetes mellitus treatment with glargine insulin or detemir insulin in Spain. Rev. Esp. Econ. Salud. 6(4), 37-43 (2007).
40. Landkvist J, Berne C, Bobader B, Joasson L. The economic and quality of life impact of hypoglycaemia. Eur. Health Econ. 50, 197-202 (2005).
41. UKPDS 37. Quality of life in Type 2 diabetes is affected by complications not by intensive policies to improve blood glucose or blood pressure control. Diabetes Care 22, 1125-1136 (1999).
42. Lammert M, Hammer M, Frier BM. Management of severe hypoglycaemia: cultural similarities, differences and resource consumption in three European countries. J. Med. Econ. 12(4), 269-280 (2009).
43. Polonsky WH, Davis CL, Jacobson AM. Correlates of hypoglycaemia fear in Type I and Type II diabetes mellitus. Health Psychol. 11, 199-202 (1992).
44. Strachan MJ. Fear of diabetes complications. Diabetes Metab. Res. 21, 262-263 (2005).
45. Shiu AT, Wong RY. Fears and worries associated with hypoglycaemia and diabetics complications: perceptions and experiencies of Hong Kong Chinese clients. J. Adv. Nurs. 39, 155-163 (2002).
46. Clar C, Barnard K, Cummins E, Royle P, Waugh N. Self-monitoring of blood glucose in Type 2 diabetes: systematic review. Health Technol. Assess. 14(12), 1-140 (2010).
47. Weber C, Schneider B, Lodwig V, Holm MV, Nesser K. Cost impact of glucose blood self-monitoring on complications of Type 2 diabetes: a Swiss Perspective (ROSSO Study n 11). Swiss Med. Wkly 137, 545-550 (2007).
48. Davis WA, Bruce DG, Davis TM. Is self-monitoring of blood glucose appropriate for all Type2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care 29(8), 1764-1770 (2006).
49. Tunis SL, Minshall ME. Self-monitoring of blood glucose in Type 2 diabetes: cost-effectiveness in the United States. Am. J. Manag. Care. 14(3), 131-140 (2008).
50. Farmer AJ, Wade AN, French DP et al. Blood glucose self-monitoring in Type 2 diabetes: a randomised controlled trial. Health Technol. Assess. 13(15), iii-iv, ix-xi, 1-50 (2009).
51. Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight Type 2 diabetic patients. Acta Diabetol. 31, 215-219 (1994).
52. Klonoff DC. New evidence demonstrates that self-monitoring of blood glucose does not improve outcomes in Type 2 diabetes - when this practice is not applied properly. J. Diabetes Sci. Technol. 2(3), 342-348 (2008).
53. Franciosi M, Pellegrini F, De Berardis G et al. The impact of blood glucose self-monitoring on metabolic control and quality of life in Type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care 24, 1870-1877 (2001).
54. Norfeldt S, Ludvigsson J. Fear and other disturbances of severe hypoglycaemia in children and adolescents with Type 1 diabetes mellitus. J. Ped. Endo. Metab. 18, 83-91 (2005).
55. Internacional Organization for Standarization. In vitro diagnostic test systems-requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. In: ISO Report 15197. Internacional Organization for Standarization, Geneva, Switzerland (2003).
56. Sheffield CA, Kane MP, Bakst G, Busch RS, Abelseth JM, Hamilton RA. Accuracy and precision of four value-added blood glucose meters: the Abbott Optium, the DDI Prodigy, the HDI True Track, and the HypoGuard Assure Pro. Diabetes Technol. Ther. 11(9), 587-592 (2009).
57. Ginsberg BH. Factors affecting blood glucose monitoring: sources of errors in measurement. J. Diabetes Sci. Technol. 3(4), 903-913 (2009).
58. Neeser K, Weber C. Cost impact of self-monitoring of blood glucose on complications of Type 2 diabetes: the Spanish perspective. Diabetes Technol. Ther-. 11(8), 509-511 (2009).
59. Tunis SL, Willis WD, Foos V. Self-monitoring of blood glucose (SMBG) in patients with Type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain. Curr. Med. Res. Opin. 26, 163-175 (2010).
60. IDF Diabetes Atlas 2009 (4th Edition) www.diabetesatlas.org/
61. European Agency for Evaluation of Medicinal Products (EMA). Note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus (2002) www.ema.europa.eu/pdfs/human/ ewp/108000en.pdf
62. Ballesta M, Perez AA, Valencia H, Tocino JA, Carral F, Aguilar M. Estimacion de los costes sanitarios ocasionados por los pacientes con diabetes mellitus Tipo 2 en el Area sanitaria Cadiz-San Fernando. Actas de Gestion Clfnica y Sanitaria www.cica.es/aliens/aescadiz/archivos%20 pdf